RxSight (RXST) investor relations material

Financial performance and guidance

• Q1 results exceeded expectations, with stable LAL sales and utilization rates observed in the quarter.

• Revenue guidance for the year was maintained, with a wide range to accommodate potential positives and negatives.

• Sequential improvement in growth rates is anticipated throughout the year, driven by easing year-over-year comparisons and improving fundamentals.

• Utilization per device is expected to remain stable around 8 LALs per LDD per month for the remainder of the year.

• Guidance incorporates potential headwinds from new competitive launches in the market.

Commercial strategy and adoption

• Adoption of LAL therapy grew rapidly post-IPO, reaching about 10% of the premium market by volume and 15% by revenue.

• Recent growth has shifted from expanding the installed base to driving same-store sales and deeper practice engagement.

• Organizational and programmatic changes have been implemented to enhance practice engagement and utilization.

• Positive feedback from practices, with efforts focused on sharing best practices and improving clinical integration.

• Rollout of new engagement programs is ongoing, with scaling expected to continue through this year and beyond.

Market dynamics and competitive landscape

• The premium IOL market remains stable, while the overall cataract market saw a slight decline in Q1.

• Premium offerings help practices offset reimbursement reductions, maintaining strong practitioner focus.

• LAL's key differentiator is its adjustability and superior clinical outcomes compared to other technologies.

• Competitive launches are expected to have only transient effects, with guidance reflecting these dynamics.